TEKT5

Across TCGA pan-cancer cohorts, TEKT5 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TEKT5 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher TEKT5 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TEKT5 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

KIRC, LUAD, and UCEC are the cancer types where TEKT5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	DFS	Median	All	0.180	0.796	.001	30	view →
LUAD	DFS	Median	All	0.263	0.668	<.001	30	view →
UCEC	DFS	Median	All	0.964	0.625	.017	8	view →
OV	OS	Median	III,IV	0.261	0.836	<.001	6	view →
STAD	OS	Median	III,IV	0.077	0.634	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TEKT5–KIRC (DFS)

Open the KIRC breakdown →